NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced a significant expansion of its global patent portfolio, signaling a major stride in the development of atrioventricular interval modulation (AVIM) therapy. With the addition of a newly issued patent on April 30, 2024, the company now boasts 110 patents worldwide aimed at treating hypertension, a condition affecting millions globally.
This comprehensive suite of patents encompasses 37 issued within the United States and 73 across other key global markets, including Europe, Japan, and China. Together, these patents cover over 1,800 claims related to AVIM therapy, underscoring the depth of Orchestra BioMed’s commitment to securing robust intellectual property rights for its innovative treatment approach.
David Hochman, CEO, Chairman, and Founder of Orchestra BioMed, highlighted the significance of this achievement, noting the rigorous effort to protect AVIM therapy’s intellectual property. “The depth and breadth of this patent estate represent over a decade of work,” Hochman stated. He further emphasized the potential of AVIM therapy to improve clinical outcomes for patients with hypertension who are also indicated for pacemaker use.
Orchestra BioMed’s strategic collaboration with Medtronic on the BACKBEAT global pivotal study underscores the industry’s confidence in AVIM therapy. The study aims to further validate the therapy’s effectiveness and safety, paving the way for its broader adoption.
The expansion of Orchestra BioMed’s patent portfolio not only strengthens the company’s position in the competitive landscape of hypertension treatment but also reflects its broader commitment to innovation in cardiac neuromodulation therapies. With additional patents expected to be granted, Orchestra BioMed is set to continue shaping the future of hypertension management, offering new hope for patients seeking effective treatment options.
This development is of particular importance as it demonstrates the value of intellectual property in fostering innovation and ensuring patients access to groundbreaking treatments. By securing extensive patent protection, Orchestra BioMed ensures the commercial viability and exclusivity of its AVIM therapy, potentially influencing the broader market for medical devices and treatments for cardiovascular conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.